Cimetidina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cimetidina

What Type of Medicine is Cimetidina?

Cimetidina refers to the synthetic chemical substance Cimetidine (INN), which is precisely categorized as a Histamine H₂-receptor antagonist or H₂-blocker. This classification defines it as a drug that acts as a competitive inhibitor of histamine at the H₂-receptors located on the gastric parietal cells. Cimetidine holds the unique distinction of being the first agent successfully developed and introduced in this pharmacological class, a pioneering role that is clinically recognized for changing the treatment approach for acid-related conditions. This distinction established Cimetidine as a standard for later H₂-blocker development, based on its established mechanism of reducing the stomach's acid output. This pharmacological action provides a method for systemically controlling acid levels in the stomach.

Composition, Forms, and General Purpose

The medicinal product is a single-ingredient entity, consisting solely of the active substance Cimetidine combined with necessary inactive pharmaceutical excipients and bases. Unlike some newer acid reducers, Cimetidina is frequently supplied in several fundamental dosage forms, including the solid tablet for oral intake, an aqueous-based oral solution suitable for liquid formulations, and a sterile preparation for parenteral (injection) use. The general therapeutic purpose of this H₂-blocker is the significant inhibition of gastric acid secretion. This mechanism is typically relied upon to alleviate the general discomfort associated with excessive stomach acid, which occurs, for instance, in conditions characterized by acid hypersecretion.

What side effects are possible with Cimetidina?

Possible Side Effects and Safety Information

Cimetidine's safety profile, as documented in official regulatory labeling, is classified primarily by the frequency and the System-Organ Class (SOC) affected. The most frequently documented adverse reactions are classified as Common.


Adverse Reaction Classification

Classification Examples of Officially Documented Effects
Common Headache, Dizziness, Diarrhea, Skin rashes, Myalgia, and Tiredness.
Uncommon Confusion, Hallucinations, Depression, and minor elevations in plasma creatinine or liver enzymes.
Rare/Very Rare Serious blood dyscrasias (e.g., Aplastic anemia, Agranulocytosis), Hypersensitivity reactions (e.g., Anaphylaxis), Hepatitis, Interstitial nephritis, and Heart block.

These effects fall into defined SOC groups, including Nervous System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Blood and Lymphatic System Disorders.


Special Safety Considerations

The medicine's safety profile includes specific considerations for certain groups. Older adults and individuals with impaired renal or hepatic function have an increased risk of neurological effects, such as reversible confusion or psychotic states, which are generally noted as resolving upon withdrawal of the drug.

Exposure-related patterns are also noted: Gynecomastia and reversible impotence are associated with high-dose or long-term exposure. Furthermore, cardiac events like bradycardia and hypotension are risks explicitly documented to occur after rapid intravenous administration.

Official labeling mandates that the possibility of a gastric malignancy must be excluded before use for gastric ulcers, as the medication may potentially mask the symptoms of a cancerous condition. The medicine is formally contraindicated in patients with a known hypersensitivity to the active substance.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documents define the Cimetidine overdose profile by detailing a range of potential clinical manifestations, although acute ingestions up to 20 grams have been reported without significant ill effects. Documented overdose presentations primarily involve the Central Nervous System (CNS), which may manifest as confusion or confusional states, drowsiness, hallucinations, and slurred speech. Cardiovascular findings include tachycardia, bradycardia, and low blood pressure (hypotension). Other potential symptoms include nausea, vomiting, diarrhea, and fever.

The official labeling identifies potential severe outcomes, including respiratory failure and serious blood dyscrasias such as neutropenia. Urgent medical help is required immediately upon suspected overdose, and users should contact a Poison Control Center. Emergency services must be called if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Management is focused on symptomatic and supportive therapy, which may include procedural steps like gastric lavage or the use of specific interventions (e.g., a beta-blocker to control tachycardia) as documented by regulators. No specific antidote is officially documented. Elderly and severely ill patients, particularly those with renal failure, are noted as having an increased risk for reversible confusional states.

Therapeutic Uses of Cimetidina

Main Uses of Cimetidina

Cimetidina is a medication classified as an H2-receptor antagonist. Its primary function is to reduce the amount of acid produced by the stomach. By inhibiting the action of histamine on the parietal cells of the gastric mucosa, it helps manage various conditions related to excessive gastric acidity.

Treatment of Gastric and Duodenal Ulcers

One of the primary applications of Cimetidina is the treatment of active benign gastric ulcers and duodenal ulcers. By decreasing acid secretion, the medication allows the mucosal lining of the stomach and the upper part of the small intestine to heal. It is also utilized in maintenance therapy after an active ulcer has healed to prevent recurrence.

Management of Gastroesophageal Reflux Disease (GERD)

Cimetidina is used to address the symptoms of gastroesophageal reflux disease. In this condition, stomach acid flows back into the esophagus, causing irritation and discomfort. The reduction in acid production helps alleviate persistent heartburn and prevents damage to the esophageal lining, such as erosive esophagitis.

Hypersecretory Conditions

The medication is indicated for pathological hypersecretory conditions, where the stomach produces abnormally high levels of acid. A primary example is Zollinger-Ellison syndrome, a rare condition characterized by the development of tumors that trigger excessive gastric acid production.

Prevention of Upper Gastrointestinal Bleeding

In clinical settings, Cimetidina may be used to prevent upper gastrointestinal bleeding in critically ill patients. It helps maintain a higher gastric pH, which reduces the risk of stress-induced mucosal damage and subsequent hemorrhaging.

Primary Benefits

  • Acid Reduction: Effectively lowers both basal and nocturnal gastric acid secretion.
  • Symptom Relief: Provides relief from discomfort associated with acid indigestion, sour stomach, and heartburn.
  • Tissue Healing: Creates an environment conducive to the repair of the gastrointestinal mucosa by limiting chemical irritation from acid.
  • Prophylactic Support: Offers a preventive measure against the recurrence of ulcers and the development of stress-related gastric injuries.

Regulatory References

  1. DailyMed Drug Label (NLM/FDA)

Eligibility and Restrictions for Use

Eligibility and Contraindications

Cimetidina's official eligibility profile is strictly defined by regulatory guidelines. The medicine is absolutely contraindicated in patients with a known hypersensitivity to cimetidine or any component of the formulation. Use is also prohibited when co-administered with specific drugs, such as dofetilide.

Age and Physiological Restrictions

The prescription product is approved for use in adults and adolescents 16 years and older. OTC use is established for individuals 12 years and older, while children under 12 should consult a doctor. Older adults require special caution due to an increased risk of central nervous system effects. Use during lactation is not recommended, and during pregnancy (Category B), it is used only when the anticipated benefit justifies the potential risk.

Condition-Based Limitations

Patients with impaired renal function require that use be approached with caution and typically mandates a dosage adjustment. Caution is also advised for those with hepatic impairment. Furthermore, treatment for gastric ulcers requires that gastric malignancy be excluded before Cimetidina administration.

What should I know about interactions with other medicines?

Cimetidine can significantly affect the body's processing of many other medications, which may lead to increased drug levels and a higher risk of side effects or toxicity. These interactions are primarily due to two mechanisms:

Inhibition of Drug Metabolism

Cimetidine is a known inhibitor of several Cytochrome P450 (CYP) enzymes in the liver, which are responsible for breaking down many drugs. By inhibiting these enzymes, cimetidine delays the clearance of the co-administered drugs, increasing their concentration in the blood. This effect is clinically significant for drugs with a narrow therapeutic index (where small changes in blood level can be dangerous). Affected medications include:

  • Anticoagulants (e.g., warfarin): Increased risk of bleeding.
  • Anti-asthma agents (e.g., theophylline): Increased risk of toxicity, such as seizures and arrhythmia.
  • Antiarrhythmics (e.g., lidocaine, quinidine):
  • Anticonvulsants (e.g., phenytoin).
  • Certain beta-blockers (e.g., propranolol, metoprolol) and benzodiazepines (e.g., diazepam).

Dosage adjustments and close patient monitoring are often required when combining these drugs with cimetidine.

Reduced Drug Absorption

Cimetidine raises the pH (reduces acidity) in the stomach. This change can decrease the absorption of certain antifungal medicines (e.g., ketoconazole, itraconazole) that require an acidic environment to dissolve. For these drugs, regulatory information recommends separating the timing of administration.

Mechanism of Action

How Cimetidina Works: Mechanism of Action

Cimetidine functions as a Histamine H2 receptor antagonist, influencing signaling pathways in the gastric system.


Competitive Blockade of Histamine H2 Receptors

This domain covers the drug's primary molecular target: the Histamine H2 receptors located on the parietal cells of the stomach lining. Cimetidine acts as a competitive antagonist, binding to these receptors to prevent endogenous histamine from initiating the acid-secreting process.

Interruption of the Gastric Acid Secretion Cascade

This mechanism operates within the humoral signaling cascade that drives acid production. By blocking the histamine signal, Cimetidine reduces the intracellular activation that leads to the mobilization of the H^+/ K^+-ATPase (the proton pump). This action results in a decrease in the volume and acidity of gastric secretions.

Peripheral Modulation of Secretory Function

This domain defines the drug's effect as peripheral, localized to the stomach tissue. The modulation alters the activity of the acid-secreting response by selectively interfering with the histamine-mediated pathway, leading to an increase in gastric pH.

Dosage and Administration Information

Official Administration Guidelines for Cimetidine

Cimetidine is administered via Oral (tablet, solution), Intravenous (IV), and Intramuscular (IM) routes, providing flexibility for outpatient and hospital settings. Usage instructions, including dose and frequency, are formalized based on the intended duration of treatment, with a maximum daily dose of 2400 mg.

Administration Schedule and Context

Regimen Type Standard Adult Dose & Frequency Course Duration Pattern
Acute Ulcer Treatment 800 mg once daily at bedtime (QHS); or 400 mg twice daily (BID); or 300 mg four times a day (QID) 4 to 8 weeks for healing.
Maintenance Therapy 400 mg once daily at bedtime. Up to 1 year or longer to reduce recurrence.
OTC Use (Prevention) 200 mg up to 30 minutes before consuming symptom-causing food or drink. Self-treatment is limited to 14 continuous days.

Oral doses in the QID regimen are typically taken with meals and at bedtime. If a dose is missed, the standard procedure is to take it as soon as possible unless the next dose is due, in which case the missed dose is skipped; doubling the dose is not recommended.

Parenteral and Population-Specific Rules

For IV administration, the injectable solution must be diluted in a compatible fluid, and IV injection must be administered slowly, over a period of not less than 5 minutes, or as an intermittent infusion over 15 to 20 minutes.

Population-Specific Dosing: A dose reduction is required for patients with severely impaired renal function (e.g., creatinine clearance less than 30 mL/min). A common adjustment is 300 mg every 12 hours. Dosing for children over one year is typically weight-based (25 to 30 mg/kg/day) in divided doses.

Recent Clinical Evidence

Cimetidina: Recent Clinical Evidence

Evidence for use in Major Depressive Disorder (MDD)

Research examined Cimetidina for Major Depressive Disorder in short-term (six to eight weeks) Randomized Controlled Trials (RCTs) conducted in adult populations. Key outcomes were changes in scores on standard depression rating scales. Research describes how studies monitored these changes, with findings describing patterns observed relative to control groups. However, the available data show patterns related to short-term changes only, and findings were mixed across different trials.

Evidence for use in Generalized Anxiety Disorder (GAD)

Cimetidina was evaluated in short-term controlled trials, typically lasting 8 to 10 weeks, focusing on Generalized Anxiety Disorder. Studies used standardized anxiety scales to track outcomes related to physical discomfort and emotional state. Research highlights changes measured during the study period, reporting patterns of score changes, but evidence quality varies across studies, meaning certainty remains low.

Evidence for use in Panic Disorder (PD)

The research explored Cimetidina for Panic Disorder in short-term studies (around 10 to 12 weeks), which are relevant in trials assessing episodic symptom patterns. The research examined outcomes describing acute changes, such as the reported frequency of panic attacks. Studies monitored and reported patterns of change over the short observation period, but findings describe group patterns, not personal outcomes.

Overall Research Limitations

The available research for Cimetidina across the studied indications has primarily focused on short-term trials (typically 6 to 12 weeks). This means that long-term effects are not fully established regarding sustained stability or safety over many months. Follow-up durations were limited, and sample sizes were modest in several research efforts. Furthermore, data for certain groups remain insufficient, including for adolescents, older adults, or those with significant comorbid conditions.

Frequently Asked Questions (FAQ)

Common questions about Cimetidina (FAQ)


Q: Why does Cimetidina sometimes cause breast tenderness in men (gynecomastia)?

A: Official regulatory data indicates that Cimetidina, particularly when used in sufficiently high doses, has demonstrated weak antiandrogenic effects.

This means the medicine can slightly influence certain hormone signaling pathways. This activity is what is associated with the rare development of breast tenderness or enlargement in men, known as gynecomastia.


Q: Can Cimetidina interact negatively with common pain relievers like ibuprofen?

A: Regulatory documents generally advise caution when using Cimetidina alongside NSAIDs (a class including ibuprofen).

The reason is not a direct drug-level increase, but rather that NSAIDs are known to potentially irritate the stomach lining, which could affect the healing of the underlying acid condition Cimetidina is treating.


Q: What is the risk of Cimetidina causing a drug interaction with blood thinners?

A: Regulatory documents explicitly warn that Cimetidina delays the clearance of certain anticoagulants (blood thinners) such as warfarin.

This interaction can lead to higher concentrations of the blood thinner in the body, which may result in a higher risk of bleeding.


Q: Does Cimetidina affect the absorption of other medicines I take?

A: Yes, official product information states that Cimetidina affects absorption due to its main action of raising the stomach’s pH (making it less acidic).

This reduction in stomach acid can decrease the absorption of certain medicines, such as specific antifungal drugs, that rely on a highly acidic environment to dissolve properly.


Q: Why is Cimetidina sometimes mentioned for treating warts?

A: Cimetidina’s primary approved use is for acid-related stomach conditions. However, some medical literature has explored the use of Cimetidina for conditions not listed on the official label, such as certain skin conditions like viral warts, hives, and itching.


Q: Can Cimetidina be taken on an empty stomach, or does it need food?

A: The required context for taking Cimetidina depends on the schedule. Prescription regimens are often advised to be taken with meals and at bedtime.

However, when used over-the-counter for heartburn prevention, it is taken up to 30 minutes before consuming symptom-causing food or drink, which may occur when the stomach is empty.


Q: Why do some people say Cimetidina has more drug interactions than other H2 blockers?

A: This is related to its activity in the liver. Cimetidina is identified as an inhibitor of several Cytochrome P450 ( CYP) enzymes, which are the liver's primary system for breaking down and removing many drugs.

By interfering with this enzyme system, Cimetidina has the potential to interact with a wide range of other medicines.


Q: Can Cimetidina be used by people who have mild liver problems?

A: Regulatory guidance advises that caution and close monitoring are necessary for people with hepatic (liver) impairment.

Individuals with liver issues may be at an increased risk for side effects, such as central nervous system effects like confusion.


Q: Why is Cimetidina considered a 'CYP inhibitor'?

A: Cimetidina is referred to as a CYP inhibitor because it binds to and blocks the activity of certain Cytochrome P450 ( CYP) enzymes in the liver.

These enzymes are crucial for breaking down and removing other drugs from the body; by inhibiting this, Cimetidina delays the clearance of those other drugs.


Q: Does Cimetidina cause problems with concentration or memory?

A: Official safety information lists that Cimetidina can cause central nervous system effects, including confusion, hallucinations, and depression.

These effects can certainly impact concentration and clear thinking, and the risk is noted to be higher in older adults or individuals with underlying kidney or liver problems.


Q: Are there any known interactions between Cimetidina and alcohol?

A: While Cimetidina may not have a critical, dangerous drug interaction with alcohol, official patient information often contains a caution against the consumption of alcohol while taking the medication.

This is usually because alcohol is known to irritate the stomach and can potentially work against the Cimetidina treatment by worsening the underlying acid condition.


Q: Is Cimetidina an over-the-counter medicine in some countries?

A: Yes, Cimetidina is available in many regions in different formats. A lower-dose version of the medicine is approved and sold for over-the-counter (OTC) use to prevent and relieve heartburn symptoms, while higher doses require a prescription.


Q: Is it true that Cimetidina was one of the first medicines of its type?

A: Yes, this is noted in pharmaceutical history. Cimetidina holds the distinction of being the first agent successfully developed and introduced in the pharmacological class known as Histamine H2-receptor antagonists.


Q: How long do the effects of Cimetidina last after one dose?

A: The duration of effect can depend on the specific dose and individual factors. Regulatory data shows that following a typical oral dose, the concentration of Cimetidina remains high enough to significantly inhibit stomach acid production for about 4 to 5 hours.

For a single nocturnal dose taken at bedtime, the acid reduction effect has been shown to last 8 hours or more.


Q: Are there any specific foods or drinks to avoid while using Cimetidina?

A: While Cimetidina does not typically have critical food-drug interactions, patient safety guidance often advises avoiding substances that are known to irritate the stomach and increase acid production.

These include drinks with caffeine and alcohol, and foods that are highly acidic or spicy, as they are known to irritate the stomach and could potentially work against the therapeutic effect.


Q: Are there different strengths of Cimetidina tablets available?

A: Yes, regulatory documents show that Cimetidina is supplied in multiple tablet strengths to suit different treatment needs. These typically include the lower strength 200 mg (often used for OTC products) and higher strengths of 300 mg, 400 mg, and 800 mg for prescription use.


Q: Why is Cimetidina sometimes used in combination with other allergy medicines?

A: Since Cimetidina is a Histamine H2 blocker, it has been observed in some instances to be used alongside traditional H1 allergy medicines.

This is done to manage certain inflammatory skin conditions, such as hives (urticaria), by achieving a broader blockade of histamine activity in the body.


Q: Can Cimetidina make me feel nauseous?

A: Official regulatory safety information for Cimetidina includes digestive disturbances. The official safety information notes that nausea is one of the possible gastrointestinal side effects that may occur during treatment.


Q: Can taking Cimetidina affect my sleep patterns?

A: Cimetidina can potentially affect sleep in two different ways. For people experiencing severe nocturnal acid reflux, taking Cimetidina can improve sleep quality by relieving symptoms.

Conversely, central nervous system side effects like drowsiness are also noted in safety data, which could affect sleep timing or patterns.


Q: Does Cimetidina help with nighttime acid reflux?

A: Yes, Cimetidina is shown to be effective for treating acid secretion that occurs at night. The dose taken at bedtime is specifically designed to suppress acid production and has been shown to reduce mean hourly acid activity over an extended eight-hour period, providing relief during sleep.


Q: What is the maximum amount of time Cimetidina can be taken continuously?

A: The maximum duration depends on the intended use. For OTC self-treatment of occasional heartburn, use is generally limited to a course of 14 continuous days.

However, prescription maintenance therapy for certain ulcers or conditions may continue for up to 1 year or longer when taken under a doctor's supervision.

How should Cimetidina be stored and disposed of?

Storage and Disposal of Cimetidine

Cimetidine tablets and solutions must be stored at Controlled Room Temperature (CRT), typically 20°C to 25°C (68°F to 77°F). The medication must be kept in a tight, light-resistant container and protected from light. Essential handling rules dictate that the oral solution must not be frozen, and the injection form should not be refrigerated to prevent crystallization.

Child Safety and Disposal

It is mandatory to keep this and all medication out of the sight and reach of children. Unused or expired Cimetidine should be disposed of through an approved drug take-back program or mail-back service. Regulatory guidelines advise against flushing Cimetidine down the toilet or throwing it in the trash without proper preparation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cimetidina found in:

A-Z Index: